Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma

NCT04304040 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT04304040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04304040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 28, 2020
Completion date
December 30, 2025
Enrollment
43 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma recurrent, b-cell lymphoma refractory